Estevo Santamarina

Estevo Santamarina

Auto-generated profile, based on publicly available information

Estevo Santamarina

Epilepsy Unit, Neurology Department. Vall d'Hebron Hospital Universitat Autònoma de Barcelona Barcelona Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Stroke
Verified
Journal Article
Open access
KSKai Michael Schubert
Kai Michael Schubert
DZDominik Zieglgänsberger
Dominik Zieglgänsberger
GBGiulio Bicciato
Giulio Bicciato
LALaura Abraira
Laura Abraira
ESEstevo Santamarina
Estevo Santamarina
MGMarian Galovic
Marian Galovic
BACKGROUND: Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. METHODS: This multicenter cohort study included data from 9 centers between 2002 and 2018, with a final analysis in February 2024. The study included 4552 adults (2005 female; median age, 73 years) with ischemic stroke and no seizure history. Seizures were classified using International League Against Epilepsy definitions. We examined ASyS occurring within 7 days after stroke. The main outcomes were all-cause mortality and epilepsy. Validation of the updated SeLECT score (SeLECT-ASyS) was performed in 3 independent cohorts (Switzerland, Argentina, and Japan) collected between 2012 and 2024, including 74 adults with ASyS. RESULTS: The 10-year risk of poststroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (adjusted hazard ratio [aHR], 2.3 [95% CI, 1.3–4.0]; P =0.003) compared with later ASyS. Status epilepticus had the highest epilepsy risk (aHR, 9.6 [95% CI, 3.5–26.7]; P <0.001), followed by focal to bilateral tonic-clonic seizures (aHR, 3.4 [95% CI, 1.9–6.3]; P <0.001). Mortality was higher in those with ASyS presenting as focal to bilateral tonic-clonic seizures on day 0 (aHR, 2.8 [95% CI, 1.4–5.6]; P =0.004) and status epilepticus (aHR, 14.2 [95% CI, 3.5–58.8]; P <0.001). The updated SeLECT-ASyS model, available as an application, outperformed a previous model in the derivation cohort (concordance statistics, 0.68 versus 0.58; P =0.02) and in the validation cohort (0.70 versus 0.50; P =0.18). CONCLUSIONS: ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.

28 January 2026 in Epilepsia
Verified
Journal Article
Open access
VVVicente Villanueva
Vicente Villanueva
JSJosé María Serratosa
José María Serratosa
AFAlejandro Fernández-Cabrera
Alejandro Fernández-Cabrera
MTManuel Toledo
Manuel Toledo
BGBeatriz González‐Giráldez
Beatriz González‐Giráldez
FRFátima Romero‐Aguilera
Fátima Romero‐Aguilera
Objectives: Cenobamate is an antiseizure medication (ASM) with proven effectiveness in individuals with highly refractory epilepsy. This study investigated the effectiveness and tolerability of cenobamate in different treatment lines and a less refractory setting. Methods: This was a multicenter, retrospective, observational study. Adults with focal epilepsy, 2–6 prior ASMs, and ≥12 months between cenobamate initiation and database closure were included. Data from patients' charts were collected and included in the Drug‐Resistant Epilepsy Registry of the Spanish Epilepsy Society using Research Electronic Data Capture. Primary effectiveness endpoints included changes in seizure frequency at 3, 6, and 12 months after cenobamate initiation according to different treatment lines. Primary safety endpoints included the percentage of patients with adverse events (AEs). Results: In total, 486 patients were included (mean age 42.8 years). The mean number of prior ASMs was 4.4 (2–6); the mean number of concomitant ASMs at cenobamate initiation was 2.5 (1–5). At 12 months, treatment retention was 92% and median dose was 200 mg. One‐year seizure‐freedom rates were 32.5%, 33.3%, 21.4%, 24.2%, and 11.4% in those treated with 2–6 prior ASMs, respectively. The proportions of patients achieving ≥50%, ≥75%, ≥90%, and 100% reductions in seizure frequency at 12 months were significantly higher in patients with 2–3 (earlier treatment lines) vs 4–6 prior ASMs (later treatment lines; p ≤ .004). Improvements in seizure severity were reported in 71.9% of patients during follow‐up (82.5% and 62.1% in those with 2 and 6 prior ASMs, respectively). At 12 months, 56.4% of patients had reported AEs, with somnolence the most frequent, and 4.9% had AEs requiring cenobamate discontinuation. Significance: Cenobamate was effective and well tolerated in patients who had tried 2–6 prior ASMs in a real‐world setting. High effectiveness was confirmed at 1 year, with better outcomes in earlier users.

1 January 2016 in Revista De Neurologia
Verified
Journal Article
Closed access
JVJaime Masjuán Vallejo
Jaime Masjuán Vallejo
JSJosé Alvarez Sabín
José Alvarez Sabín
SRSusana Arias Rivas
Susana Arias Rivas
MGMiguel Blanco González
Miguel Blanco González
AMAlicia de Felipe Mimbrera
Alicia de Felipe Mimbrera
BABeatriz Zandio Amorena
Beatriz Zandio Amorena

28 October 2023 in Epilepsia
Verified
Journal Article
Closed access
ESEstevo Santamarina
Estevo Santamarina
MRMarc Rodrigo‐Gisbert
Marc Rodrigo‐Gisbert
LALaura Abraira
Laura Abraira
DCDaniel Campos‐Fernández
Daniel Campos‐Fernández
MQManuel Quintana
Manuel Quintana
MTManuel Toledo
Manuel Toledo

9 November 2025 in Epilepsia
Verified
Journal Article
Open access
ESEstevo Santamarina
Estevo Santamarina
LALaura Abraira
Laura Abraira
DCDaniel Campos‐Fernández
Daniel Campos‐Fernández
MQManuel Quintana
Manuel Quintana
EFElena Fonseca
Elena Fonseca
MTManuel Toledo
Manuel Toledo
Objective: This study was undertaken to identify novel blood‐based biomarkers associated with the early diagnosis of status epilepticus (SE) by exploring proteomic alterations in plasma extracellular vesicles (EVs). Methods: We conducted an observational and prospective study in a two‐phase design: a discovery proteomic analysis of plasma EVs from 16 patients (eight with SE and eight matched non‐SE), followed by a validation phase using basic immunodetection techniques in a separate cohort of 160 patients (80 SE, 80 non‐SE) for selected proteins in plasma. Proteomic profiling was performed with liquid chromatography–tandem mass spectrometry, and protein interaction networks were explored using STRING and Cytoscape software platforms. Results: In the discovery phase, 2046 proteins were identified, and 977 met inclusion criteria. CDH1, APOC4, and IGHG2 showed the highest differential expression in SE patients. Network analysis revealed strong interactions involving SLC4A1 and SRC. In the validation cohort, levels of APOC4, CDH1, SLC4A1, and S100B were significantly higher in SE patients ( p < .05). In the multivariate logistic regression model, only APOC4, S100B, and SLC4A1 remained independently associated with SE diagnosis. A combined model including these proteins predicted SE with 84.6% accuracy (95% confidence interval = 64.3%–94.9%). Other proteins, including NSE and HMGB1, showed no significant differences. Significance: This study identifies new plasma biomarkers that may support the early diagnosis of SE, particularly in emergency settings where access to electroencephalography is limited. These findings suggest potential applicability to clinical practice; nevertheless, prospective validation in independent and larger cohorts is required.

11 October 2025 in Epilepsia
Verified
Journal Article
Closed access
EFElena Fonseca
Elena Fonseca
ATAlejandro Thomson
Alejandro Thomson
MAMario Alonso
Mario Alonso
ÓCÓscar Contreras
Óscar Contreras
WCWalter de la Cruz
Walter de la Cruz
MTManuel Toledo
Manuel Toledo